Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Rawan G FaramandSae Bom LeeMichael D JainBiwei CaoXuefeng WangMarion SubkleweMarion SubkleweJohannes F FahrmannNeeraj Y SainiSamir M HanashYun Pyo KangDarwin ChangPaulo C RodriguezErin A DeanTaiga NishihoriBijal D ShahAleksander LazaryanJulio C ChavezFarhad KhimaniJavier A Pinilla-IbarzMarian DamKayla M ReidSalvatore A CoralloMeghan MengesMelanie Hidalgo VargasJessica K MandulaBrian A HollidayChristina A BachmeierKelly A SpethQinghua SongMike MattieFrederick L LockeMarco L DavilaPublished in: Blood cancer discovery (2024)
CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80.
Keyphrases
- diffuse large b cell lymphoma
- cell therapy
- end stage renal disease
- epstein barr virus
- chronic kidney disease
- ejection fraction
- newly diagnosed
- acute myeloid leukemia
- stem cells
- prognostic factors
- acute lymphoblastic leukemia
- mesenchymal stem cells
- peritoneal dialysis
- oxidative stress
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- hodgkin lymphoma
- patient reported
- replacement therapy